使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q3 2025 earnings conference call. (Operator Instructions) This call is being recorded on Monday, November 10, 2025.
各位女士、先生,早安,歡迎參加 ADC Therapeutics 2025 年第三季財報電話會議。(接線員指示)本通話將於 2025 年 11 月 10 日(星期一)錄音。
I will now turn the call over to Nicole Riley, Head of Investor Relations and Corporate Communications for ADC Therapeutics. Nicole, please go ahead.
現在我將把電話交給 ADC Therapeutics 投資人關係與企業傳播主管 Nicole Riley。Nicole,請開始。
Nicole Riley - Investor Relations
Nicole Riley - Investor Relations
Thank you, operator. Today, we issued a press release announcing our third-quarter 2025 financial results and business updates. This release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website.
謝謝,接線員。今天我們發布新聞稿,公布 2025 年第三季財務結果與業務更新。該新聞稿以及我們今天簡報將使用的投影片,可於 ADC Therapeutics 官網的投資人專區取得。
I'm joined on today's call by our Chief Executive Officer, Ameet Mallik, who will discuss our operational performance and recent business highlights; our Chief Medical Officer, Mohamed Zaki, who will discuss our clinical programs and updates; followed by our Chief Financial Officer, Pepe Carmona, who will review our third-quarter 2025 financial results. We will then open the call to questions.
今天與會者包括我們的執行長 Ameet Mallik,他將說明營運表現與近期業務重點;我們的首席醫療長 Mohamed Zaki,他將說明臨床計畫與最新進展;接著由我們的財務長 Pepe Carmona 回顧 2025 年第三季財務結果。之後我們將開放提問。
Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain known and unknown risks and uncertainties and actual results, performance and achievements could differ materially. They are identified and described in the accompanying slide presentation and in the company's filings with the SEC, including Form 10-K 10-Q and 8-K.
在開始之前,我想提醒各位聽眾,本次電話會議中的部分陳述將構成前瞻性陳述,符合 1995 年《美國私人證券訴訟改革法》安全港條款之定義。這些前瞻性陳述受到若干已知與未知風險及不確定性影響,實際結果、表現與成就可能存在重大差異。相關風險已於隨附的投影片簡報以及公司向美國證券交易委員會(SEC)提交的文件中識別並加以說明,包括 Form 10-K、10-Q 與 8-K。
ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events, or circumstances, except as required by law. The company cautions investors not to place undue reliance on these forward-looking statements.
ADC Therapeutics 係以今日日期提供本資訊,除法律要求外,對於因新資訊、未來事件或情勢所致而需更新本次電話會議中任何前瞻性陳述,公司不承擔任何義務。公司提醒投資人勿過度依賴這些前瞻性陳述。
Today's presentation also includes non-GAAP financial reporting. These non-GAAP measures should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with GAAP. You should refer to the company's third-quarter earnings release for information and reconciliation of historical non-GAAP measures to the corporate GAAP financial measures.
今天的簡報亦包含非 GAAP 財務報告。這些非 GAAP 指標應與依 GAAP 編製之資訊一併考量,而不應單獨使用,亦不應作為其替代。請參閱公司第三季財報新聞稿,以取得歷史非 GAAP 指標與公司 GAAP 財務指標之相關資訊與調節表。
I will now turn the call over to our CEO, Ameet Mallik. Ameet?
現在我將把電話交給我們的執行長 Ameet Mallik。Ameet?
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Thanks, Nicole, and hello, everyone. Thank you for joining us on today's call. In the third-quarter of 2025, we continue to focus on execution and delivering on our commercial strategy, maintaining ZYNLONTA as a differentiated treatment option for third-line plus DLBCL patients while advancing data across key trials. Net product revenues were $15.8 million in the third-quarter, reflecting variability in customer ordering patterns and were broadly in line with the quarterly run rate over the past two years.
謝謝你,Nicole,各位大家好。感謝各位參加今天的電話會議。在 2025 年第三季,我們持續聚焦於執行力並落實商業策略,在推進關鍵試驗數據的同時,維持 ZYNLONTA 作為第三線以上 DLBCL 病患具差異化的治療選項。第三季產品淨營收為 1,580 萬美元,反映客戶下單模式的波動,整體而言與過去兩年的季度常態水準大致一致。
We continue to progress against our key ZYNLONTA trials in second-line plus DLBCL and expect to share additional data in the coming months. We plan to provide an update on LOTIS-7, our Phase Ib trial evaluating ZYNLONTA in combination with the bispecific antibody, glofitamab, before the end of the year. Then in the first half of 2026, we plan to announce top line results from LOTIS-5, our Phase III confirmatory trial of ZYNLONTA in combination with rituximab, once the prespecified number of PFS events is reached and data are available.
我們持續推進 ZYNLONTA 在第二線以上 DLBCL 的關鍵試驗,並預期在未來數月分享更多數據。我們計畫在年底前提供 LOTIS-7 的最新進展;該試驗為一期 Ib,評估 ZYNLONTA 與雙特異性抗體 glofitamab 的合併治療。接著在 2026 年上半年,一旦達到預先規定的 PFS 事件數且數據可用,我們計畫公布 LOTIS-5 的主要結果;LOTIS-5 為 ZYNLONTA 與利妥昔單抗(rituximab)合併治療的三期確認性試驗。
Within indolent lymphomas, the lead investigator on the Phase II IIT of ZYNLONTA in combination with rituximab recently presented encouraging updated relapsed or refractory follicular lymphoma data at the 22 International Workshop on Non-Hodgkin Lymphoma. The trial is on track to enroll 100 patients. In addition, the Phase II IIT of ZYNLONTA in relapsed or refractory marginal zone lymphoma continues to enroll to the target of 50 patients. Beyond ZYNLONTA, we continued with IND-enabling activities for our PSMA-targeting ADC, which are on track to be completed by the end of the year.
在惰性淋巴瘤方面,近期 ZYNLONTA 與利妥昔單抗合併治療之二期研究者發起試驗(IIT)的主要研究者,於第 22 屆非霍奇金淋巴瘤國際研討會上發表了令人鼓舞的復發或難治性濾泡性淋巴瘤更新數據。該試驗正按計畫招募 100 名病患。此外,ZYNLONTA 用於復發或難治性邊緣區淋巴瘤的二期 IIT 亦持續招募,目標為 50 名病患。除 ZYNLONTA 之外,我們也持續推進針對 PSMA 的 ADC 之 IND 申請前(IND-enabling)活動,並按計畫將於年底前完成。
Lastly, just after the quarter end, we secured a $60 million private placement led by TCGX, including participation from Redmile Group and other existing investors. This financing takes our expected cash runway at least to 2028. With our strengthened balance sheet, I am confident that we are well positioned to further invest in ZYNLONTA as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas.
最後,在季度結束後不久,我們完成 6,000 萬美元的私募融資,由 TCGX 領投,Redmile Group 及其他既有投資人亦參與。此項融資使我們預期的現金可支撐期至少延長至 2028 年。隨著資產負債表的強化,我有信心我們已具備良好條件,能進一步投資 ZYNLONTA;我們預期將其推進至 DLBCL 更早線別治療,並拓展至惰性淋巴瘤。
As a single-agent therapy in third-line plus DLBCL, ZYNLONTA has a profile of rapid, deep, and durable efficacy as well as manageable safety with simple and convenient administration. Beyond our current indication, we believe in the potential to reach significantly more patients by expanding use into earlier lines of therapy in DLBCL and into indolent lymphomas. The data we've seen across these settings so far has been consistently encouraging with the potential to be highly differentiating.
作為第三線以上 DLBCL 的單藥治療,ZYNLONTA 具備快速、深度且持久的療效特徵,同時安全性可控,且給藥方式簡單便利。除目前適應症外,我們相信透過將使用擴展至 DLBCL 更早線別治療以及惰性淋巴瘤,可觸及顯著更多病患。迄今我們在這些情境中所見數據一貫令人鼓舞,且具高度差異化的潛力。
We continue to believe that through expansion into these settings, ZYNLONTA has the potential to reach peak annual revenues of $600 million to $1 billion in the US. Our current indication has, as I noted earlier, shown relative stability in net revenues over multiple quarters, demonstrating ZYNLONTA has a clear place in the market as a monotherapy.
我們仍然相信,透過拓展至上述情境,ZYNLONTA 在美國的年度峰值營收有機會達到 6 億至 10 億美元。如我先前所述,我們目前適應症的淨營收在多個季度呈現相對穩定,顯示 ZYNLONTA 作為單藥治療在市場上具有明確定位。
We believe LOTIS-5 has the potential to lift peak annual revenue for ZYNLONTA to $200 million to $300 million as we expand into the second-line setting. Not only would this double the addressable patient population, but with an improved clinical profile versus our current indication as a monotherapy, we expect to gain share in the second-line plus setting and improved duration of therapy.
我們認為 LOTIS-5 有潛力在我們拓展至第二線治療情境時,將 ZYNLONTA 的年度峰值營收提升至 2 億至 3 億美元。這不僅將可服務的病患族群規模加倍,且相較於目前單藥適應症具更佳的臨床特徵,我們預期在第二線以上情境中可提升市占,並延長治療持續時間。
With LOTIS-7, we estimate we can expand the total opportunity for ZYNLONTA in DLBCL to $500 million to $800 million in peak annual revenue with both regulatory approval and compendia listing. If the data continue to be compelling, we believe ZYNLONTA plus glofitamab has the potential to transform the future lymphoma treatment paradigm by becoming the preferred bispecific combination in the second-line plus DLBCL setting.
就 LOTIS-7 而言,我們估計在取得法規核准與收錄於治療指引彙編(compendia)後,可將 ZYNLONTA 在 DLBCL 的整體機會擴大至年度峰值營收 5 億至 8 億美元。若數據持續具說服力,我們相信 ZYNLONTA 加上 glofitamab 有潛力透過成為第二線以上 DLBCL 情境中首選的雙特異性合併方案,改變未來淋巴瘤治療典範。
On top of this, we see additional potential for ZYNLONTA in relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. If the encouraging initial data in the Phase II IITs are maintained in larger patient numbers, we believe these indolent lymphomas could provide additional peak annual revenue for ZYNLONTA of $100 million to $200 million with both regulatory approval and compendia listing, primarily driven by MZL.
此外,我們也看到 ZYNLONTA 在復發或難治性邊緣區淋巴瘤以及復發或難治性濾泡性淋巴瘤方面的額外潛力。若二期 IIT 的初步鼓舞數據在更大病患數中得以維持,我們相信這些惰性淋巴瘤在取得法規核准與收錄於治療指引彙編(compendia)後,可為 ZYNLONTA 帶來額外年度峰值營收 1 億至 2 億美元,主要由 MZL 驅動。
Let's drill down a little more into the specifics of the DLBCL treatment landscape to explain why we believe ZYNLONTA has the opportunity to play a significant role. In both the second and third-line plus settings, there are two main segments.
接下來我們更深入說明 DLBCL 治療版圖的細節,以解釋為何我們認為 ZYNLONTA 有機會扮演重要角色。在第二線以及第三線以上情境中,主要可分為兩大區隔。
The first segment includes complex therapies which require unique infrastructure and expertise to handle logistical requirements and patient management. These are primarily confined to the academic centers and more sophisticated community centers and includes therapies like CAR T, transplant and bispecifics. The second segment comprises more broadly accessible therapies which all physicians can administer in the outpatient setting and includes ADCs, monoclonal antibodies, and chemotherapy.
第一個區隔包含複雜療法,需具備特定基礎設施與專業能力,以因應物流需求與病患管理。這些療法主要侷限於學術醫學中心及較成熟的社區醫療中心,包括 CAR T、移植以及雙特異性療法等。第二個區隔則由更廣泛可及的療法構成,所有醫師皆可於門診環境施行,包括 ADC、單株抗體與化學治療。
The launch of bispecifics as monotherapy in the third-line plus setting has resulted in an evolution of the treatment landscape, where we estimate there is currently a 60-40 split between complex and broadly accessible segments. In the second-line setting where bispecifics have not yet been approved but were recently added to NCCN guidelines for use in combination, we expect that they will continue to gain share and grow the use of complex therapies.
雙特異性抗體以單藥形式在三線及以上治療情境中的推出,促使治療版圖演進;我們估計目前複雜治療與廣泛可及治療兩個區隔的占比約為60-40。在二線治療情境中,雙特異性抗體尚未獲批,但近期已被納入NCCN指南、可用於聯合治療;我們預期其將持續提升市占,並帶動複雜治療的使用成長。
Through LOTIS-5 and LOTIS-7, we believe ZYNLONTA combinations have the potential to raise the bar on efficacy in second-line plus DLBCL in their respective treatment segments, offering complementary approaches to addressing unmet needs. In LOTIS-5, our Phase III confirmatory study, we are combining ZYNLONTA with the most widely used agent, rituximab, in patients with second-line plus DLBCL.
透過LOTIS-5與LOTIS-7,我們相信ZYNLONTA聯合療法在各自的治療區隔中,有潛力在二線及以上DLBCL的療效標準上更上一層樓,並以互補方式滿足未被滿足的醫療需求。在我們的第三期確認性研究LOTIS-5中,我們將ZYNLONTA與使用最廣泛的藥物利妥昔單抗(rituximab)聯合,用於二線及以上DLBCL患者。
As a reminder, initial data from the safety lead-in portion showed an overall response rate of 80% and a complete response rate of 50% with no new safety signals, demonstrating that this combination has the potential to provide competitive second-line plus efficacy with a favorable safety profile, allowing broad accessibility.
提醒一下,安全性導入(safety lead-in)部分的初步數據顯示,總反應率為80%,完全反應率為50%,且未出現新的安全性訊號,顯示此聯合療法有潛力在二線及以上提供具競爭力的療效,並具備良好的安全性特徵,有助於廣泛可及。
In LOTIS-7, our Phase Ib trial, we are combining ZYNLONTA with a highly effective bispecific, glofitamab, in second-line plus patients. Data presented in June at EHA and ICML based on the April 2025 cutoff showed the combination was generally well tolerated with a manageable safety profile.
在我們的第一期b(Phase Ib)試驗LOTIS-7中,我們將ZYNLONTA與一款高效的雙特異性抗體glofitamab聯合,用於二線及以上患者。於6月在EHA與ICML發表、以2025年4月為資料截止日的數據顯示,該聯合療法整體耐受性良好,且安全性特徵可管理。
Furthermore, we believe it demonstrated clinically meaningful benefit with an overall response rate of 93.3% and a complete response rate of 86.7% across 30 efficacy-evaluable patients. We are encouraged by the promising early data, which we believe demonstrates the potential for ZYNLONTA plus glofitamab to be a best-in-class combination in a highly competitive market.
此外,我們認為其在30名可評估療效的患者中展現具臨床意義的獲益,總反應率為93.3%,完全反應率為86.7%。我們對這些令人鼓舞的早期數據感到振奮,並相信其顯示ZYNLONTA加glofitamab在高度競爭的市場中有潛力成為同類最佳(best-in-class)的聯合療法。
When you look at the CR rates among both currently available and emerging therapies in these two treatment segments, we believe the emerging clinical profile of ZYNLONTA plus glofitamab in the LOTIS-7 trial positions us well among complex therapies and, at the same time, the clinical profile of ZYNLONTA plus rituximab in the LOTIS-5 trial has the potential to differentiate us among broadly accessible therapies.
當你觀察這兩個治療區隔中目前可用與新興療法的完全反應(CR)率時,我們認為LOTIS-7試驗中ZYNLONTA加glofitamab逐步成形的臨床特徵,使我們在複雜治療中具備良好定位;同時,LOTIS-5試驗中ZYNLONTA加利妥昔單抗的臨床特徵,也有潛力讓我們在廣泛可及治療中形成差異化。
Together, we believe these combinations have the potential to double the addressable patient population as we move into the second line and increase the duration of therapy moving on average from three cycles to five to six cycles.
我們相信,隨著我們進入二線治療,這些聯合療法合計有潛力使可觸及的患者族群倍增,並將治療持續時間由平均三個療程延長至五到六個療程。
Now I will turn the call over to our Chief Medical Officer, Mohamed Zaki, who will share the latest on the Phase II follicular lymphoma IIT data. Mohamed?
現在我把電話交給我們的首席醫療官Mohamed Zaki,他將分享第二期濾泡性淋巴瘤IIT數據的最新進展。Mohamed?
Mohamed Zaki - Chief Medical Officer
Mohamed Zaki - Chief Medical Officer
Thank you, Ameet. I am pleased to share updated data from the Phase II investigator-initiated trial of ZYNLONTA in combination with rituximab in relapsed/refractory follicular lymphoma. The data were presented in September at the 22 International Workshop on Non-Hodgkin Lymphoma by the lead investigator, Dr. Juan Pablo Alderuccio, from the Sylvester Cancer Center, part of the University of Miami Miller School of Medicine.
謝謝你,Ameet。我很高興分享ZYNLONTA聯合利妥昔單抗用於復發/難治性濾泡性淋巴瘤的第二期研究者發起試驗(investigator-initiated trial)的更新數據。這些數據於9月在第22屆國際非霍奇金淋巴瘤研討會上,由主要研究者、來自Sylvester癌症中心(邁阿密大學米勒醫學院的一部分)的Juan Pablo Alderuccio醫師發表。
Data presented from the 55 efficacy-evaluable patients to date in this trial continues to demonstrate encouraging results with an overall response rate of 98.2% and a complete response rate of 83.6%. After median follow-up of 28 months, median PFS was not reached and the 12-month PFS was 93.9%. In this trial, no new safety signals were observed and safety was consistent with the known profile of ZYNLONTA.
截至目前,本試驗中55名可評估療效患者的發表數據持續顯示令人鼓舞的結果:總反應率為98.2%,完全反應率為83.6%。在中位隨訪28個月後,中位無進展存活期(PFS)尚未達到,12個月PFS為93.9%。本試驗未觀察到新的安全性訊號,安全性與ZYNLONTA已知特徵一致。
The University of Miami is actively enrolling towards a target of 100 high-risk relapsed/refractory follicular lymphoma patients and is opening the study at additional US cancer research centers. As soon as sufficient data are available, we plan to assess regulatory and update the compendia pathways.
邁阿密大學正積極招募,目標為100名高風險復發/難治性濾泡性淋巴瘤患者,並正在更多美國癌症研究中心啟動該研究。一旦取得足夠數據,我們計畫評估法規路徑並更新藥典(compendia)路徑。
Now I will turn the call over to Pepe Carmona, our CFO, who will discuss financial results for the third-quarter. Pepe?
現在我把電話交給我們的財務長Pepe Carmona,他將討論第三季的財務結果。Pepe?
Jose Carmona - Chief Financial Officer
Jose Carmona - Chief Financial Officer
Thank you, Mohamed. On the financial front, ZYNLONTA net product revenues in the third-quarter of 2025 were $15.8 million as compared to $18 million in the same quarter in 2024. Total operating expenses for the quarter were $45 million on a non-GAAP basis, representing a 12.1% net decrease over prior year. The reduction was primarily driven by lower R&D expenses with sales and marketing expenses stable year-over-year. We continue to be disciplined in our capital allocation towards potential value creation while driving efficiencies across the portfolio.
謝謝你,Mohamed。在財務方面,ZYNLONTA於2025年第三季的產品淨營收為1,580萬美元,較2024年同期的1,800萬美元下降。本季非GAAP口徑的總營運費用為4,500萬美元,較去年同期淨減少12.1%。費用下降主要由研發(R&D)費用降低所驅動,銷售與行銷費用則與去年同期大致持平。我們在資本配置上持續保持紀律,聚焦於潛在價值創造,同時推動整體產品組合的效率提升。
On a GAAP basis, we reported a net loss of $41 million for the second-quarter of 2025 or $0.30 per basic and diluted share as compared to a net loss of $44 million or $0.42 per basic and diluted share for the same period in 2024. The decrease in net loss for the quarter is primarily attributable to lower R&D and G&A expenses. You can find the reconciliation of GAAP to non-GAAP measures for the third-quarter and year-to-date in the accompanying financial tables of the press release issued earlier today and in the appendix of this presentation.
按GAAP口徑,我們在2025年第二季錄得淨損4,100萬美元,或每股基本及稀釋虧損0.30美元;相較之下,2024年同期淨損為4,400萬美元,或每股基本及稀釋虧損0.42美元。本季淨損縮小主要歸因於研發以及一般與行政(G&A)費用降低。你可在今日稍早發布的新聞稿所附財務表格,以及本簡報附錄中,查閱第三季與年初至今GAAP與非GAAP衡量指標的調節表。
At the end of the quarter, we had cash and cash equivalents of $234.7 million, which compared to $250.9 million as of December 31, 2024. In October, we entered into a $60 million PIPE financing which, on a pro forma basis, expanded our cash and cash equivalents to approximately $292.3 million as of that date. The strengthening of our balance sheet allows us to execute our strategy with an expected cash runway extending at least to 2028.
截至本季末,我們的現金及約當現金為2.347億美元,較2024年12月31日的2.509億美元下降。10月,我們完成6,000萬美元的PIPE私募投資融資;按備考(pro forma)口徑計算,截至該日期我們的現金及約當現金增加至約2.923億美元。資產負債表的強化使我們得以執行策略,並預期現金可支撐營運至少延續至2028年。
Across the LOTIS-5, LOTIS-7, and MZL ZYNLONTA programs, we expect to have data catalysts in the remainder of 2025 and 2026. For LOTIS-5, we expect to provide top line data in the first half of 2026 once the prespecified number of PFS events is reached and data are available, assuming positive results and supplemental biologic license application submission to regulatory authorities will follow with potential confirmatory approvals in second-line plus DLBCL as well as publication and compendia inclusion in the first half of 2027.
在LOTIS-5、LOTIS-7以及MZL的ZYNLONTA計畫中,我們預期在2025年剩餘期間及2026年將出現多項數據催化劑。就LOTIS-5而言,一旦達到預先設定的PFS事件數且數據可用,我們預期於2026年上半年提供主要(top line)數據;若結果為正,我們將向監管機構提交補充生物製劑許可申請(sBLA),並有望在二線及以上DLBCL取得確認性核准,同時於2027年上半年完成發表並納入藥典(compendia)。
With LOTIS-7, following presentation of the data at EHA and ICML in June, we observed an acceleration in enrollment in the study at the selected 150-microgram per kilogram dose level. We plan to provide a clinical update on all efficacy-evaluable patients with a minimum of six months of follow-up through a corporate announcement before the end of the year. Once sufficient data with longer follow-up are available, we plan to engage with the FDA.
在LOTIS-7方面,繼6月於EHA與ICML發表數據後,我們觀察到研究在所選定的150微克/公斤劑量水平的入組速度加快。我們計畫在年底前透過公司公告,針對所有可評估療效且至少隨訪六個月的患者提供臨床更新。一旦取得隨訪時間更長的充分數據,我們計畫與FDA展開溝通。
In addition, assuming positive results, we plan to pursue publication and compendia inclusion in the first half of 2027. With indolent lymphomas, we expect additional data to be shared at medical conferences by the lead investigators, and we plan to assess regulatory and compendia strategies once sufficient data are available. Beyond ZYNLONTA, we continue to advance our exatecan-based PSMA-targeting ADC with completion of IND-enabling activities anticipated towards the end of this year.
此外,若結果為正,我們計畫於2027年上半年推進發表並納入藥典(compendia)。在惰性淋巴瘤方面,我們預期主要研究者將在醫學會議上分享更多數據;待取得足夠數據後,我們將評估法規與藥典策略。除ZYNLONTA之外,我們也持續推進以exatecan為基礎、靶向PSMA的ADC,並預期在今年底前完成IND申報前的關鍵支持性工作(IND-enabling activities)。
I will now turn the call back over to Ameet.
我現在把電話交回給Ameet。
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Thank you, Pepe. Let me close by saying that I'm pleased with how we are executing against our strategy and continue to be excited by the consistently encouraging ZYNLONTA data we are generating across our ongoing trials. We have a clear vision to unlock the true potential of the company with multiple potential value-creating milestones ahead and a balance sheet that enables us to deliver on our strategy. We can now open the line for questions. Operator?
謝謝你,Pepe。最後我想說,我對我們在策略執行上的表現感到滿意,並且對我們在各項進行中的試驗中持續產出一貫令人鼓舞的 ZYNLONTA 數據仍感到振奮。我們有清晰的願景,將透過多個可能創造價值的里程碑來釋放公司真正的潛力,同時我們的資產負債表也使我們能夠落實策略。我們現在可以開放提問。接線員?
Operator
Operator
(Operator Instructions)
(接線員指示)
Eric Schmidt, Cantor.
Eric Schmidt,Cantor。
Eric Schmidt - Analyst
Eric Schmidt - Analyst
Maybe on LOTIS-7, intrigued by Pepe's comments that we're seeing accelerated enrollment post the June data release. Not surprising, of course. But can you frame how many patients we might get later this quarter? And then in terms of your target enrollment out of 100 or so patients, are you adjusting that target? And is it possible that target could be achieved sooner rather than later?
想請教 LOTIS-7 的部分,我對 Pepe 提到在 6 月數據發布後入組加速的評論很感興趣。當然這並不令人意外。但你能否說明一下本季稍晚我們可能會再入組多少名病人?另外,就你們約 100 名病人的目標入組數而言,你們是否在調整這個目標?以及是否有可能比預期更早達成該目標?
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Thanks for the question, Eric. Yes, no, we've been pleased that since the EHA and ICML update, we've had even greater interest in the trial and enrollment definitely accelerated. We're still targeting the roughly 100 patients that we've been targeting to enroll. It will occur quicker than what we originally anticipated. We're not giving any exact timeline. We're still confirming the first half of next year to have that completed.
謝謝你的問題,Eric。是的,我們很高興自從 EHA 和 ICML 的更新之後,試驗受到更大的關注,入組確實加速。我們仍以約 100 名病人的入組目標為準。完成速度會比我們原先預期更快。我們不提供任何確切時間表。我們仍確認在明年上半年完成。
Eric Schmidt - Analyst
Eric Schmidt - Analyst
And then in terms of the upcoming data release, Ameet, are you still targeting 40 or 40-plus?
那麼就即將發布的數據而言,Ameet,你們仍以 40 或 40 以上為目標嗎?
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Well, we'll give -- as you recall, we have enrolled originally 20 patients in each dose and then we continue to expand at the 150 dose, right? So it will clearly be more than the original 20 and 20 but it won't be fully all 100. And also, I want to make sure you heard what Pepe said, is that we're going to be sharing update on all efficacy-evaluable patients with a minimum six months follow-up. This is because it provides more stable, meaningful updates both in terms of the depth of response but also the durability of response.
嗯,我們會提供——如你所記得的,我們最初在每個劑量組各入組 20 名病人,然後我們持續在 150 劑量組擴增,對吧?所以很明顯會多於原本的 20 加 20,但不會是完整的 100 名。另外,我想確保你有聽到 Pepe 說的:我們將分享所有可評估療效病人的更新,且至少有 6 個月的追蹤期。這是因為它能提供更穩定、更有意義的更新,不僅在反應深度方面,也在反應持久性方面。
That was -- as you may recall, some of the questions we received in the early updates is we had very limited follow-up. So now we're focused on where the data is more stable, and that's really the patients with the minimum of six months follow-up.
如你可能記得的,在早期更新時我們收到的一些問題是追蹤期非常有限。所以現在我們聚焦在數據更穩定的部分,也就是至少有 6 個月追蹤期的病人。
Operator
Operator
Clara Dong, Jefferies.
Clara Dong,Jefferies。
Jenna Li - Equity Analyst
Jenna Li - Equity Analyst
This is Jenna Li on the line. Could you talk about, in the context of the upcoming LOTIS-5 and LOTIS-7 data and the submission timeline, when should we expect to see an inflection point for ZYNLONTA sales? And could you also give some qualitative comment on the pace of revenue ramp-up once you have those potentially positive data or approval in hand?
我是 Jenna Li 在線上。想請你談談,在即將公布的 LOTIS-5 與 LOTIS-7 數據以及申報時程的背景下,我們應該何時預期 ZYNLONTA 銷售出現拐點?另外,一旦你們取得這些可能正面的數據或核准,你能否就營收爬坡的速度提供一些定性的評論?
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
So I think you're asking about the milestones and then also the revenue inflection. So first, I would say, for LOTIS-7, we expect to share an interim update on data later this year and, obviously, we expect to have full data sometime by the end of next year or into the first half of 2027. As you can see, what we guided to is publication and/or compendia inclusion sometime between the end of next year and the first half of 2027.
我想你問的是里程碑以及營收拐點。首先,我會說,對於 LOTIS-7,我們預期在今年稍晚分享一次期中數據更新,而顯然我們預期在明年年底左右或到 2027 年上半年某個時間點取得完整數據。如你所見,我們給出的指引是:在明年年底到 2027 年上半年之間的某個時間點完成發表和/或納入彙編(compendia inclusion)。
With LOTIS-5, we expect to share top line results in the first half of 2026 and then have approval sometime in the first half of 2027. So if you think of the revenue ramp-up for those two, following compendia inclusion and approvals, which we expect for both in the first half of 2027, we expect revenues to ramp up subsequent to that.
至於 LOTIS-5,我們預期在 2026 年上半年分享主要結果(top line results),並在 2027 年上半年某個時間點取得核准。因此,如果你思考這兩項的營收爬坡,在彙編納入與核准之後——我們預期兩者都在 2027 年上半年——我們預期營收會在其後逐步加速成長。
Jenna Li - Equity Analyst
Jenna Li - Equity Analyst
Sorry, just a quick follow-up. Did you also have any comments on the pace of ramp-up following first half '27?
抱歉,快速追問一下。你對 2027 年上半年之後的爬坡速度也有任何評論嗎?
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Yes. I mean, I don't want to guide to the exact ramp-up. What I will say is if you look at other launches, whether it's the bispecifics or Polivy in the front line or others, I would say the majority of the ramp-up happens during the first two years post launch or approval or compendia listing of a new indication. It's typically -- the majority is going to happen in the first two years.
有。我的意思是,我不想對確切的爬坡速度給出指引。但我會說,如果你看其他產品上市,不論是雙特異性抗體,或是 Polivy 在一線治療的上市,或其他案例,我會說大部分的爬坡發生在新適應症上市、核准或納入彙編後的前兩年。通常——大部分會發生在前兩年。
Operator
Operator
Michael Schmidt, Guggenheim Securities.
Michael Schmidt,Guggenheim Securities。
Unidentified Participant
Unidentified Participant
This is [ Sarah ] on for Michael. So I just wanted to get your thoughts on with these newer agents moving into frontline DLBCL, is that something that you are or would consider pursuing for ZYNLONTA?
我是代替 Michael 的 [Sarah]。我想請教,隨著這些較新的藥物進入 DLBCL 一線治療,你們是否正在或會考慮讓 ZYNLONTA 也往一線治療方向發展?
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Yes. And I think the frontline will be interesting because if you look at the frontline setting, for decades really, R-CHP was the standard of care. And then only a couple of years ago, you saw Polivy R-CHP get approval, and that was based on a marginal improvement in PFS without an overall survival benefit. But of course, the safety looked good and that's been actually pretty widely adopted. So frontline is the high bar is my point.
會的。我認為一線治療會很有意思,因為如果你看一線治療領域,數十年來 R-CHP 一直是標準治療。而且直到幾年前,你才看到 Polivy R-CHP 獲得核准,那是基於 PFS 的些微改善,但沒有整體存活期(overall survival)的獲益。但當然,安全性看起來不錯,而且實際上已被相當廣泛地採用。所以我的重點是:一線治療的門檻很高。
One of the biggest things being studied right now are bispecifics, and I think there's some excitement about. If those could have potential, still to be determined. I think we're still a little bit of ways away from seeing those readouts. And in terms of our future development, we'll consider how that goes for this combination post the readout of the 100 patients.
目前研究中最大的一類是雙特異性抗體,我認為大家對此有些期待。它們是否可能帶來潛力,仍有待確認。我想我們距離看到那些讀出結果還有一段時間。至於我們未來的開發方向,我們會在這個組合完成 100 名病人的讀出之後,再評估後續如何推進。
And obviously, any support would depend on a partner, too. I don't see us likely funding a Phase III study with this in the frontline or the second-line setting with this combination purely on our own. Yes, we're watching the space closely.
而且很明顯,任何進一步推進也會取決於合作夥伴的支持。我不認為我們很可能會單靠自己資助這個組合在一線或二線治療的第三期試驗。是的,我們會密切關注這個領域。
Operator
Operator
Leonid Timashev, RBC Capital Markets.
Leonid Timashev,RBC Capital Markets。
Leonid Timashev - Equity Analyst
Leonid Timashev - Equity Analyst
I just want to ask on sort of the split of community and academic. I know you've talked about LOTIS-5 potentially being more positioned in the broadly applicable therapies and the LOTIS-7 more for the academic. But I guess I'm curious how neat you think those breakdowns actually are going to be and sort of how you're going to balance ultimately where patients are found and how you want to focus your sales force across academic and community to sort of pursue the opportunity where it is.
我想問一下社區端與學術端的分布。我知道你們談過 LOTIS-5 可能更偏向廣泛適用的治療,而 LOTIS-7 更偏向學術端。但我好奇你們認為這些區分實際上會有多明確,以及你們最終會如何在病人來源與銷售團隊在學術端與社區端的投入之間取得平衡,以便在機會所在之處加以把握。
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Yes. So I wouldn't do the breakdown in terms of academic and community. What I'd say is for the more complex therapies, whether it's CAR T or bispecifics, let's just talk about bispecifics because that's more applicable to LOTIS-7. They're not only used across all of the academic centers. They are used in more sophisticated community centers and that may grow over time. So I wouldn't say it's distinction of purely community versus academic. It's more all of the academic can administer those products and a portion of the community can administer those products.
是的。所以我不會用學術端與社區端來做切分。我會說,對於較複雜的治療,不論是 CAR T 或雙特異性抗體——我們就談雙特異性抗體,因為它與 LOTIS-7 更相關。它們不只在所有學術中心使用。它們也會在較成熟的社區中心使用,而且這種使用範圍可能會隨時間擴大。所以我不會說這是純粹社區對學術的區分。更像是:所有學術中心都能施用這些產品,而社區端中有一部分中心也能施用這些產品。
In that universe of institutions that can administer the product, obviously, LOTIS-7 is going to have a clear place. Then there's other therapies like chemotherapy, ADCs, antibodies, which are more broadly accessible and those can be ministered across all settings. But they are still administered in the academic centers and they're administered in all the community settings. So I wouldn't differentiate to say LOTIS-7 is going to be purely academic and LOTIS-5 is going to be purely community.
在那個能夠施行該產品的機構體系中,很明顯,LOTIS-7 會有其明確定位。另外還有其他療法,例如化學治療、ADC、抗體等,這些可近性更廣,且可在各種場域施行。但它們仍會在學術中心施行,也會在所有社區醫療場域施行。因此我不會區分說 LOTIS-7 只會在學術中心、而 LOTIS-5 只會在社區端。
The reality is LOTIS-7, when a patient is suitable for it and the facility can administer the therapy, you're going to go with the highest-efficacy product and a combination that you can go with. We think LOTIS-7 is really well positioned, and that will be used again in all the academic centers and a portion of the community. Exactly how much, we'll see over time how bispecifics get adopted by the community.
現實是,對於 LOTIS-7,只要病人適合且院所能施行該療法,你就會選擇療效最高的產品與你能採用的組合。我們認為 LOTIS-7 的定位非常好,並且會再次在所有學術中心使用,也會在部分社區端使用。至於比例究竟有多少,我們會隨時間觀察雙特異性抗體在社區端的採用情況。
With LOTIS-5, either because of accessibility of the therapy or because of suitability for the patient, remember, there are some patients that have co-morbidities or other conditions which may prevent them from getting an immune-based therapy subsequently. There may be a post-CAR T patient that's at risk of infection, may be a patient with autoimmune disease. There may be other reasons why you're not going to want to give a bispecific-based therapy. And for other centers in the community, they're not going to have access to them.
至於 LOTIS-5,可能因為療法的可近性,或因為病人的適用性;請記得,有些病人有共病或其他狀況,可能會使他們之後無法接受免疫為基礎的療法。可能是 CAR T 後的病人有感染風險,也可能是有自體免疫疾病的病人。也可能有其他原因,使你不會想給予以雙特異性為基礎的療法。而對於社區中的其他中心,他們也不會有取得這些療法的管道。
And so for all those reasons, we think LOTIS-5 still plays a big role. We still see R-based chemo regimens having a large share in the relapse/refractory market. So we think we have a good place, and that's really our strategy, is to hopefully have leading efficacy in both of these segments, both the complex therapies and the more broad accessible therapies.
因此基於上述所有原因,我們認為 LOTIS-5 仍扮演重要角色。我們仍看到以 R 為基礎的化療方案在復發/難治市場中占有相當大的比重。所以我們認為我們有很好的定位;而這也確實是我們的策略:希望在這兩個區隔中都能具備領先的療效,也就是在複雜療法與更廣泛可近的療法兩者皆然。
Operator
Operator
(Operator Instructions)
(接線員指示)
Sudan Loganathan, Stephens.
Sudan Loganathan,Stephens。
Sudan Loganathan - Equity Analyst
Sudan Loganathan - Equity Analyst
I know you've spoken about the opportunity in the second-line, third-line plus for relapsed/refractory DLBCL with LOTIS-7, LOTIS-5 outcomes, respectively. But can you give us more details on how you view each percentage increase in penetration in either the second or third-line setting would add to the ZYNLONTA revenues to achieve your peak guidance ranges that you've noted?
我知道你們談過 LOTIS-7 與 LOTIS-5 在復發/難治 DLBCL 的二線、三線以上治療中的機會與各自的結果。但你們能否提供更多細節,說明你們如何看待在二線或三線以上任一治療線別中,每增加 1 個百分點的滲透率,會如何為 ZYNLONTA 的營收帶來增量,以達到你們所提到的峰值指引區間?
And then secondly, regarding the ZYNLONTA plus rituximab for relapsed/refractory FL, data thus far at 84% CR rate seems to slide nicely right after the T cell therapeutics and then in line or slightly better than bispecifics. If this holds true, does this mostly take market share away from bispecifics? Or any opportunity to take from the T cell therapeutic options in FL? I'd like to get your details on those things.
第二個問題,關於 ZYNLONTA 加上利妥昔單抗用於復發/難治 FL,目前數據顯示 CR 率達 84%,看起來很適合定位在 T 細胞療法之後,且與雙特異性抗體相當或略優。如果這個結果能維持,這主要會從雙特異性抗體那邊取得市占嗎?或是在 FL 方面,也有機會從 T 細胞治療選項那邊取得一些份額?想請你們就這些提供更詳細的看法。
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Yes. So I would say to answer your first question about what's the share point worth, so think about in the second-line setting, there's about 12,000 patients in the US and in the third-line plus setting, there's 6,000 patients. So depending on where you're getting the share, the second-line setting or third-line plus, every share point obviously multiplied by the number of patients.
是的。我會這樣回答你第一個問題,也就是每一個市占百分點的價值:二線治療在美國大約有 12,000 名病人,而三線以上大約有 6,000 名病人。因此取決於你取得市占的場域是在二線或三線以上,每一個市占點當然就是乘上相對應的病人人數。
With monotherapy, we're typically seeing three cycles. Now remember, the first two doses of our product are at 150 micrograms per kilogram and then it drops to 75. So it's weight-based. But oftentimes, it can be two vials for the first two cycles and drop to one vial. What we're seeing with LOTIS-5 and LOTIS-7 is somewhere between five to six cycles.
以單藥治療而言,我們通常看到三個療程。請記得,我們產品前兩次給藥的劑量是每公斤 150 微克,之後會降到 75。所以是依體重計算。但很多時候,前兩個療程可能需要兩瓶(vial),之後降為一瓶。而我們在 LOTIS-5 與 LOTIS-7 看到的療程數大約介於五到六個療程。
So you can just do the subsequent calculation on vials and then you know what our net price. And our gross price is in the upper $20,000s, net price is in the lower $20,000. So if you do the kind of calculation depending on what -- if you're talking about a share point in the second-line or third-line plus in, that kind of gives you a rough estimate.
所以你可以依瓶數做後續計算,然後你也知道我們的淨價格。我們的牌價在 2 萬多美元的高段,淨價格在 2 萬多美元的低段。因此你可以依你所談的是二線或三線以上的每一個市占點,做這類計算,便能得到一個粗略估算。
Just by way of example, like in the LOTIS-5, for example, if we were able to maintain our roughly 10% share that we have in the third-line plus setting and translate that in second-line setting but with increased duration of therapy and our net pricing, that would take our product, which is on roughly $70 million run rate, that's what it's kind of been the last couple of years, to just over $200 million. Obviously, we're hoping with efficacy improvements, you actually gain share. And that's what leads to the guidance of $200 million to $300 million. You can do similar calculation for LOTIS-7.
舉例來說,以 LOTIS-5 而言,如果我們能維持目前在三線以上約 10% 的市占,並把它轉移到二線治療,但同時治療持續時間更長、且以我們的淨定價計算,這會讓我們的產品從目前約 7,000 萬美元的年化營收(過去幾年大致如此)提升到略高於 2 億美元。當然,我們希望隨著療效提升,你實際上能夠提高市占。而這也就是 2 億到 3 億美元指引的來源。你也可以對 LOTIS-7 做類似的計算。
Now turning to the indolent lymphomas. I think we're excited both about the data that Mohamed spoke about with the relapsed/refractory follicular lymphoma and relapsed/refractory marginal zone lymphoma data that was presented at EHA and ICML. I think both right now on outstanding results. I would say in terms of the opportunity for potential adoption, right now we're basically funded to try to get compendia for both. So obviously, we will promote either of these indications.
接著談惰性淋巴瘤。我們對 Mohamed 所提到的復發/難治濾泡性淋巴瘤,以及在 EHA 與 ICML 發表的復發/難治邊緣區淋巴瘤數據都感到振奮。我認為目前兩者都是非常出色的結果。就潛在採用機會而言,目前我們基本上有資金去嘗試讓兩者都納入藥典(compendia)。因此很明顯,我們會推廣這兩個適應症中的任何一個。
But what I could say is the unmet need and the level of competition is probably higher -- the unmet need is higher in MZL and the level of competition is lower in MZL versus follicular lymphoma. That's why we emphasize that one to a bit more. When you look at the different agents that are approved or in compendia, the SCR rates are 29%, roughly 30%. Even if you look at subsequent data that's come out, maybe a bit higher than that. What we've been showing is closer to 70% CR in the MZL setting.
但我可以說的是,未被滿足的需求程度與競爭強度可能更高——在 MZL 的未被滿足需求更高,而 MZL 的競爭程度相較於濾泡性淋巴瘤更低。這也是我們更強調 MZL 的原因。當你看不同已核准或已納入藥典的藥物,SCR 率約為 29%,大約 30%。即便看後續公布的數據,可能也只是略高一些。而我們在 MZL 場景所呈現的結果更接近 70% 的 CR。
In follicular, although the data is outstanding and we hope to have a place there, it's a lot more competitive. There's literally more than 10 agents that have Phase III trials, including the bispecifics and many other agents who have large Phase III studies with overall survival. And it's just a more competitive space. So that's why we think the potential for uptake is just smaller, not because the data isn't excellent, but just because it's a much more competitive space.
在濾泡性淋巴瘤方面,雖然數據非常出色,我們也希望能有一席之地,但競爭要激烈得多。實際上有超過 10 個藥物進入第三期試驗,包括雙特異性抗體以及許多其他藥物,且有大型第三期研究以總生存期為終點。這就是一個競爭更激烈的領域。因此我們認為其採用的潛力較小,並不是因為數據不夠好,而是因為競爭環境更為激烈。
Operator
Operator
There are no further questions at this time. I will now turn the call over to Ameet Mallik for closing remarks.
目前沒有其他問題。我現在把電話交回給 Ameet Mallik 做結語。
Ameet Mallik - Chief Executive Officer, Director
Ameet Mallik - Chief Executive Officer, Director
Well, I want to thank you all for joining our call today. We really appreciate the questions and we appreciate your continued support. We look forward to keeping you updated on our progress. Operator, you may now end the call.
好的,我想感謝各位今天參加我們的電話會議。我們非常感謝各位的提問,也感謝各位持續的支持。我們期待持續向各位更新我們的進展。接線員,您現在可以結束通話。
Operator
Operator
Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.
各位女士、先生,今天的電話會議到此結束。感謝各位參與,並請各位掛斷電話線。